Leslie A. Brun Resigns from Merck Board of Directors
August 20 2021 - 4:45PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, announced today that Leslie A. Brun, its independent lead
director, has resigned from its Board of Directors, effective
August 19, 2021. Mr. Brun is stepping down due to his decision to
become chairman and chief executive officer of Ariel Alternatives,
LLC, a subsidiary of Ariel Investments, LLC, a private equity
initiative being created to help scale minority-owned businesses to
serve as tier 1 suppliers to Fortune 500 companies. Merck is
currently evaluating making an investment with Ariel
Alternatives.
“Les has been an invaluable member of Merck’s board for many
years and we have benefitted greatly from his leadership, wise
counsel and friendship,” said Rob Davis, chief executive officer
and president, Merck. “While we will miss him, we recognize the
importance of the task Les is undertaking at Ariel Alternatives,
and we wish him great success.”
The company intends to name a new independent lead director in
the near future.
About Merck
For 130 years, Merck, known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases in
pursuit of our mission to save and improve lives. We demonstrate
our commitment to patients and population health by increasing
access to health care through far-reaching policies, programs and
partnerships. Today, Merck continues to be at the forefront of
research to prevent and treat diseases that threaten people and
animals – including cancer, infectious diseases such as HIV and
Ebola and emerging animal diseases – as we aspire to be the premier
research-intensive biopharmaceutical company in the world. For more
information, visit www.merck.com and connect with us on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210820005238/en/
Media Contacts: Patrick Ryan (973) 275-7075 Melissa Moody (215)
407-3536 Investor Contacts: Peter Dannenbaum (908) 740-1037 Raychel
Kruper (908) 740-2107
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024